| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2647 |
| Trial ID | NCT04834869 |
| Disease | Adverse Reaction to Vaccine |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax;CVnCoV |
| Co-treatment | AZD1222|CoronaVac|Sinopharm|Gam-COVID-Vac|JNJ-78436735|NVX-CoV2373|BBV152|CanSino |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Recruitment status | Recruiting |
| Title | COVID-19 Vaccines Safety Tracking: Global Consortium Study |
| Year | 2021 |
| Country | Canada|Croatia|Czechia|Estonia|Ethiopia|Germany|Ghana|Mexico|Poland|Portugal|Russian Federation|Serbia|Slovenia|United States |
| Company sponsor | Masaryk University |
| Other ID(s) | CoVaST |
| Vector information | |||
|
|||
| Cohort1: BNT162b2 | |||||||
|
|||||||
| Cohort2: mRNA-1273 | |||||||
|
|||||||
| Cohort3: AZD1222 | |||||||
|
|||||||
| Cohort4: CoronaVac | |||||||
|
|||||||
| Cohort5: Sinopharm | |||||||
|
|||||||
| Cohort6: Gam-COVID-Vac | |||||||
|
|||||||
| Cohort7: JNJ-78436735 | |||||||
|
|||||||
| Cohort8: CVnCoV | |||||||
|
|||||||
| Cohort9: NVX-CoV2373 | |||||||
|
|||||||
| Cohort10: BBV152 | |||||||
|
|||||||
| Cohort11: CanSino | |||||||
|
|||||||